Miltefosine--the long-awaited therapy for visceral leishmaniasis?
Herwaldt
B L
BL
D000284:Administration, Oral; D000981:Antiprotozoal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine